1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (234)
  2. Journal Article (208)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (460)
  2. Early Drug Development Service (460)
  3. Solid Tumor Oncology Division (460)
  4. GSK Faculty (243)
  5. Department of Pathology and Laboratory Medicine (200)
  6. Human Oncology and Pathogenesis Program (193)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (122)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (5)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (111)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (22)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (126)
  2. American Association for Cancer Research (100)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (460)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection
    Meeting Abstract

    Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors
    Meeting Abstract

    Hyman, D. M.; Tran, B.; Jaime, J. C.; Garralda, E.; Machiels, J. P. H.; Schellens, J. H. M.; Bedard, P.; Campone, M.; Cassier, P.; Sarantopoulos, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Hyman, D. M.; Rasco, D. W.; Infante, J. R.; Liu, J. F.; Welkowsky, E.; Thai, D. L.; Haqq, C. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Heins, Z. J.; Connell, L. C.; Soumerai, T.; Kemeny, N. E.; Jarnagin, W. R.; O'Reilly, E. M.; DeMatteo, R. P.; D'Angelica, M. I.; Lowery, M. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas
    Meeting Abstract

    Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; Masters, T.; Carvajal, R. D.; Song, S.; Kumar, P.; Gajee, R.; Zernovak, O.; Rosen, M. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A. E.; Hong, D. S.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Frequent clinical overlap of histiocytic neoplasms and WHO-classified myeloid malignancies leads to functional insights into the cell-of-origin of histiocytoses
    Meeting Abstract

    Durham, B. H.; Yoshimi, A.; Papo, M.; Chung, Y. R.; Ozkaya, N.; Ganzel, C.; Dogan, A.; Hyman, D. M.; Park, C. Y.; Rampal, R. K.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Mutational analysis of clonal hematopoiesis in solid tumor patients illustrates the critical role of systemic anti-cancer therapies in the evolution of somatic leukemia disease alleles
    Meeting Abstract

    Coombs, C. C.; Zehir, A.; Devlin, S.; Kishtagari, A.; Hyman, D. M.; Solit, D.; Robson, M.; Baselga, J.; Arcila, M.; Tallman, M. S.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Vemurafenib in patients with Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study
    Meeting Abstract

    Diamond, E. L.; Subbiah, V.; Lockhart, C.; Blay, J. Y.; Faris, J. E.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J. S.; Erinjeri, J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save